Breaking News, Collaborations & Alliances

CStone, Pfizer Enter Antibody Alliance

To support CStone’s development of sugemalimab, a potential best-in-class PD-L1 antibody being developed for high-incidence cancer indications in China.

By: Contract Pharma

Contract Pharma Staff

CStone Pharmaceuticals and Pfizer Investment Co. Ltd. and Pfizer Corporation Hong Kong Limited (both of which are subsidiaries of Pfizer Inc.) have formed a strategic collaboration that encompasses a $200 million equity investment by Pfizer Hong Kong in CStone, collaboration between CStone and Pfizer Investment for the development and commercialization of CStone’s sugemalimab (CS1001, PD-L1 antibody) in mainland China, and a framework between CStone and Pfizer Investment to bring additional onco...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters